تحميل
NASDAQHealthcareMedical - Diagnostics & Research
أحدث البيانات المتاحة
15.00 US$
−0.49 US$ · -3.16%
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
أحدث البيانات المتاحة
15.00 US$
−0.49 US$ · -3.16%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
59
قيمة عادلة
المشاعر
52
مختلط
المخاطر
74
مخاطر مرتفعة
الزخم
28
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (CNY) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 539.57 مليون CNY | 515.82 مليون CNY | 537.44 مليون CNY | 563.24 مليون CNY | 507.86 مليون CNY |
| تكلفة البضاعة المباعة | 136.65 مليون CNY | 153.42 مليون CNY | 174.21 مليون CNY | 183.2 مليون CNY | 143.72 مليون CNY |
| الربح الإجمالي | 402.91 مليون CNY | 362.4 مليون CNY | 363.23 مليون CNY | 380.04 مليون CNY | 364.15 مليون CNY |
| البحث والتطوير | 166.49 مليون CNY | 232.29 مليون CNY | 347.02 مليون CNY | 421.87 مليون CNY | 367.86 مليون CNY |
| مصاريف البيع والمصاريف العمومية والإدارية | 291.27 مليون CNY | 452.54 مليون CNY | 685.53 مليون CNY | 938.58 مليون CNY | 793.35 مليون CNY |
| نفقات التشغيل | 457.76 مليون CNY | 719.96 مليون CNY | 1.03 مليار CNY | 1.36 مليار CNY | 1.16 مليار CNY |
| دخل الفوائد | 8.05 مليون CNY | 12.21 مليون CNY | 17.96 مليون CNY | 9.46 مليون CNY | 3.46 مليون CNY |
| مصاريف الفوائد | 30 ألف CNY | — | — | — | 1.54 مليون CNY |
| الاستهلاك والإطفاء | 21.76 مليون CNY | 52.2 مليون CNY | 133.4 مليون CNY | 124.1 مليون CNY | 47.77 مليون CNY |
| الدخل التشغيلي | −54.85 مليون CNY | −357.56 مليون CNY | −669.32 مليون CNY | −980.41 مليون CNY | −797.06 مليون CNY |
| صافي الدخل | −55.35 مليون CNY | −346.63 مليون CNY | −653.69 مليون CNY | −971.23 مليون CNY | −796.7 مليون CNY |
تم تحديث حقائق الشركة 13 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Schwab International Equity ETFSCHF19.19 مليون0.03%67.41 مليار USD0.03%27.13 US$-0.51%
Schwab Fundamental International Large Company Index ETFFNDF18.04 مليون0.07%25.32 مليار USD0.25%53.42 US$-0.35%
State Street SPDR Portfolio Developed World ex-US ETFSPDW13.09 مليون0.03%40.7 مليار USD0.03%49.69 US$-0.58%
State Street SPDR Portfolio Europe ETFSPEU352.25 ألف0.05%689.36 مليون USD0.07%53.02 US$-0.21%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA258.96 ألف0.03%1.02 مليار USD0.30%97.45 US$-0.24%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX202.3 ألف0.04%487.88 مليون USD0.20%53.12 US$-0.38%
State Street SPDR MSCI World StrategicFactors ETFQWLD14.47 ألف0.01%175.94 مليون USD0.30%156.61 US$+0.15%Schwab International Equity ETFSCHFSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXState Street SPDR MSCI World StrategicFactors ETFQWLDالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
